Recent Headlines
AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children’s Hospital
AveXis, Inc., a synthetic biology platform company, today announced that the first patient in the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now been enrolled and dosed by Nationwide Children’s Hospital. This trial utilizes chariSMA, the gene therapy product developed... - June 26, 2014 - AveXis Inc.
iPathwayGuide Now Available in Illumina’s BaseSpace Apps
Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis. iPathwayGuide is a web based pathway analysis tool that goes beyond the typical statistical... - June 25, 2014 - Advaita Corporation
UCR (Uppsala Clinical Research Center) Selected Ethical eAdjudication® to Support the Clinical Endpoints Adjudication Process
Uppsala Clinical Research Center (UCR), a top Academic Research Organization based in Sweden, adopted Ethical eAdjudication® cloud-based platform to manage the central assessment of Clinical Trial Endpoints by an independent CEC (Clinical Endpoint Classification) Committee. - June 21, 2014 - Ethical GmbH
AveXis to Present at Piper Jaffray GenomeRX Symposium
AveXis, a clinical stage synthetic biology platform company, today announced that Mr. John Carbona, Chief Executive Officer and other members of the AveXis team will participate in the panel discussion “The Power Alley: Gene Therapy For Neuromuscular Disorders” at the Piper Jaffray... - June 20, 2014 - AveXis Inc.
Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay
AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit. - June 12, 2014 - AnaSpec, EGT Group
AveXis to Present at Families of Spinal Muscular Atrophy Annual Conference
AveXis, a clinical stage synthetic biology platform company, today announced that Dr. Allan Kaspar, Chief Scientific Officer, will be presenting at The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference, which will be held on Thursday, June 12, 2014 in National... - June 08, 2014 - AveXis Inc.
Industry's First Fluorimetric Assay for Glutaminyl Cyclase
AnaSpec Launches Industry’s First Fluorimetric, 96-well format Assay for Measurement of Glutaminyl Cyclase (QC) Activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit. - May 29, 2014 - AnaSpec, EGT Group
Life Science Strategy Group Launches the OutsourcePharma Advisory Board
Online community dedicated to pharmaceutical sponsors provides open forum to discuss drug development and outsourced Contract Research Organization (CRO) services. - May 28, 2014 - Life Science Strategy Group, LLC
AveXis Announces Opening of Enrollment for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children's Hospital
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced that the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now formally begun enrollment at Nationwide Children’s Hospital. This trial will utilize chariSMA, the gene therapy product developed... - May 16, 2014 - AveXis Inc.
BiologicsCorp Launches Supernatant Protein Expression Service
BiologicsCorp proudly launches this new service - another first in the industry. They have tested many variables, including codon optimization, strain, charperones and foldases, and others. Give Supernatant Service a try, especially if your protein of interest could not be expressed in soluble form. BiologicsCorp is confident and can guarantee success - no soluble fraction for target protein, no payment for expression service. - April 25, 2014 - BiologicsCorp
AveXis Closes a Round of Financing from PBM Capital to Advance Its SMA Gene Therapy Program
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced it has completed a financing round led by PBM Capital Group. This round of financing will help support the company’s gene therapy program targeting spinal muscular atrophy (SMA). AveXis’ gene therapy... - April 23, 2014 - AveXis Inc.
Dr. Kristy Ainslie Strengthens Drug Delivery Focus as She Becomes Advisor to Peptineo
Peptineo is pleased to welcome Dr. Ainslie to advisory board at Peptineo. Dr. Ainslie received her PhD in Chemical Engineering from Penn State, and after a short post doc in a start up company focused on biosensor development, Protiveris, she completed a post doc at UCSF. During her post doc, she... - April 08, 2014 - Peptineo
Dr. Applegate to Join Advisory Board at Peptineo
Peptineo is pleased to welcome Dr. Robert Applegate to the advisory board of Peptineo. Dr. Applegate is a recognized expert in microfluidics, biomedical devices and optical technologies. As a result of his research, Dr. Applegate holds patents in optical trapping, cell diagnostics and sorting, and... - April 07, 2014 - Peptineo
Peptineo, a Biotechnology Company Focused on Value Recovery in Pharma, Announces the Appointment of Kamal Garcha PhD., to Advisory Board
"We welcome the addition of Dr. Garcha," noted Sheldon K. Jordan, PhD, CEO. Dr. Garcha holds an Honor’s BSC in Cell Biology and MSc. in Zoology from Western University, and a PhD. in Cellular & Physiological Sciences from the University of British Columbia. During the course of... - April 02, 2014 - Peptineo
OsoBio Appoints Catherine Buck Director of Manufacturing
Buck has 20-plus years of experience managing pharma and commercial manufacturing plants. - April 02, 2014 - OSO BioPharmaceuticals Manufacturing, LLC
Peptineo Adds Dr. Yoganathan to Advisory Board to Strengthen Biomaterials Development and Commercialization
Dr. Yoganathan is a SME in the areas of biomaterials and drug delivery - having collaborated and worked closely with thought-leaders in the field such as Dr. Robert Langer, Dr. Kazunori Kataoka, Dr. Michael V. Sefton and Dr. Christine Allen. He is an expert in manipulating material properties to... - March 31, 2014 - Peptineo
Peptineo Announces Appointment of David M. Wyatt to Advisory Board
Peptineo is pleased to announce the appointment of David M. Wyatt to their advisory board. David has had over 25 years of technical and business experience in the development of controlled release pharmaceutical products. He has held senior management positions in sales and business development,... - March 27, 2014 - Peptineo
Dr. Sundar Nadarajan Joins the Advisory Board at Peptineo to Guide Nanotechnology Drug Delivery Platform for Protein Therapeutics
Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Sundar Nadarajan, PhD, to the company's Scientific Advisory Board. They are extremely pleased that Dr. Nadarajan has joined the Peptineo Scientific Advisory Board. "He is an accomplished scientist and consulting... - March 27, 2014 - Peptineo
Creative Biomart Launches New Services: Protein Labeling & Conjugation
Creative Biomart has announced the launch of a new offering for protein labeling and conjugation. - March 13, 2014 - Creative BioMart
AnaSpec Now Offers 5-Hydroxymethyl Cytosine Monoclonal Antibody (Clone 4D9)
A mouse monoclonal antibody specifically recognizing 5-hydroxymethyl Cytosine (5-hmC) is now available from AnaSpec. - February 21, 2014 - AnaSpec, EGT Group
FDAnews Announces Device Supplier Controls Virtual Conference, Feb. 26
Device Supplier Controls: Does the FDA’s Next 483 Have Your Name on It? FDAnews Virtual Conference Feb. 26, 2014 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/SupplierControlsVCPR2 - February 13, 2014 - FDAnews
EightSpokes Announces the Launch of Their Online Presence
EightSpokes, creators of Enlighten, a SaaS-based commercial excellence platform designed with life science companies in mind, announces the launch of their online presence, EightSpokes.com. The website highlights the “Noble Eightfold Path” that inspired the company’s approach to make work more rewarding. Enlighten adopts proven social collaboration technologies and ideas from industry leaders to put teams and team members at the center of every project’s successful execution. - January 29, 2014 - EightSpokes
Dr. George Tegos Joins Advisory Board at Peptineo to Guide Antimicrobial Pipeline and Technology Development
Peptineo, a biotechnology company focused on value recovery in Pharma, announces the appointment of George Tegos, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Tegos has joined the Peptineo Scientific Advisory Board. Dr. Tegos is recognized as an emerging... - January 29, 2014 - Peptineo
Dr. Eric Bachelder Joins Advisory Board at Peptineo
Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Eric Bachelder, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Bachelder has joined the Peptineo Scientific Advisory Board. Dr. Bachelder is recognized as an emerging... - January 18, 2014 - Peptineo
Biostratus Corporation Announces Issuance of US Patent for Tissue Bulking and Tissue Generation Technologies
Medical biotechnology company Biostratus Corporation has today announced the issuance of the USPTO Patent #8,586,089 titled "Enhanced Carriers for the Delivery of Microparticles to Mammalian Tissues and Fluids." The Biostratus patent covers a novel class of biocompatible injectable... - January 17, 2014 - Biostratus Corporation
Kimberley Beauford Joins Peptineo as Vice President of Human Capital
Industry veteran and accomplished executive, Kimberley Beauford has joined Peptineo as its new vice president of human capital. Beauford brings over 14 years of proven expertise in the delivery of innovative, strategic human capital programs to the finance and healthcare industries. Prior to... - January 14, 2014 - Peptineo
Creative Biomart Releases New Recombinant Protein Products-Human MET Mutants
Creative Biomart announces that it has launched a series of new recombinant human MET mutants. - January 11, 2014 - Creative BioMart
OsoBio Reaffirms DCAT Partnership Through New Leadership Positions
OsoBio President Milton Boyer to serve as vice president of DCAT's executive committee. - December 19, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
International Polymer Solutions (IPS) Awarded ISO-9001:2008 Certification
ISO-9001:2008 Quality Certification granted to producer of plastic components for pharmaceutical, semiconductor, laboratory and other environments. International Polymer Solutions (IPS) is proud to announce their recent certification. - December 16, 2013 - International Polymer Solutions Inc.
American Regent, Inc. Takes Center Stage on The Balancing Act® Airing on Lifetime Talkshow
Make sure to tune in to The Balancing Act on December 11th and 18th at 7:00 am (ET/PT) as Blood specialist Dr. Lawrence Tim Goodnough, blood disease expert and Lynell D'Sylva, BSN, RN from American Regent explain what IDA is and introduce their innovative treatment option. - December 10, 2013 - American Regent, Inc.
Peptineo Inks Exclusive Option for Drug Delivery Technologies
Peptineo, a privately held biotechnology company, announced today that the company has inked an exclusive option for a broad set of nanotechnology patents in the area of drug delivery. Under this agreement, Peptineo will work to commercialize drug delivery technologies developed in the laboratories... - December 10, 2013 - Peptineo
Creative Biomart Introduces New Elisa Kits to Offer More Convenient and Effective Solutions
In the early November, Creative Biomart decided to introduce new Elisa Kits which include Developmental proteins ELISA kits, Granzymes and perforins ELISA kits and Growth factors/hormones ELISA kits. - November 20, 2013 - Creative BioMart
Creative Biomart Decides to Pump $300 Million to Strengthen Biosimilar Cell Lines Production
Today on the annual department meeting, Creative BioMart announces that it plans to invest more than $300 million to strengthen its biosimilar cell lines production in global range. The domain sectors of Creative BioMart are recombinant proteins, antibodies and enzymes. Several years ago, the... - November 17, 2013 - Creative BioMart
Creative Biomart Announces Commercial Agreement for Services of Biosimilar Cell Lines Manufacturing
Creative Biomart announced today that it has signed a commercial agreement for contract manufacturing pharmaceutical biosimilar cell lines for a big pharma company. - November 10, 2013 - Creative BioMart
FDAnews Announces the FDA Unique Device Identification (UDI) Rule Virtual Conference, Nov. 19
The FDA Unique Device Identification (UDI) Rule; It’s Ready for You, Are You Ready for It? FDAnews Virtual Conference; Nov. 19, 2013 — 10:00 a.m. – 4:00 p.m. EST; www.fdanews.com/UDIVirtualPR2 - November 07, 2013 - FDAnews
AveXis-BioLife Launch New Website
AveXis-BioLife is pleased to announce the launch of the company’s brand new website: www.avexisinc.com. The October 2013 unveiling of the website coincides with the company’s licensing of the gene therapy program from The Kaspar Laboratory for the treatment of Spinal Muscular Atrophy... - November 01, 2013 - AveXis Inc.
AnaSpec Introduces SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit
SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit is used for measuring TEV protease quantity and activity. TEV protease is widely used to remove fusion tags from recombinant proteins. - November 01, 2013 - AnaSpec, EGT Group
AveXis-BioLife Licenses Spinal Muscular Atrophy (SMA) Patent Portfolio from Nationwide Children's Hospital and The Ohio State University
BioLife, a synthetic biology platform company soon to be renamed AveXis, has been granted exclusive rights to the spinal muscular atrophy gene therapy program developed at The Research Institute at Nationwide Children’s Hospital and The Ohio State University in Columbus, Ohio. The license... - October 21, 2013 - AveXis Inc.
Creative Biomart Releases New Products in the Middle of Oct.
In the middle of Oct., Creative Biomart releases a new batch a products, including: Ÿ Recombinant Human MUSK, GST-tagged Ÿ Recombinant Human TIRAP, His-tagged Ÿ Native Mouse Hb Ÿ Recombinant Human NCAM2, GST-tagged Ÿ Recombinant Human NBPF15, His-tagged Ÿ Recombinant... - October 19, 2013 - Creative BioMart
AveXis BioLife Announce The Research Institute at Nationwide Children’s Hospital Received Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children’s Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular... - October 18, 2013 - AveXis Inc.
FDAnews Workshop: Medical Device Risk Management Conference, Nov. 5-6, Chicago, IL
Medical Device Risk Management; Beyond FMEA - New Tools to Assure Your Risk Management Program Meets New Standards *Presented by Ombu Enterprises and FDAnews* Nov. 5-6, 2013 — Chicago, IL; www.fdanews.com/MDRiskPR2 - October 04, 2013 - FDAnews
FDAnews Announces Cybersecurity Threats to Medical Devices Webinar, Oct. 18
Cybersecurity Threats to Medical Devices: Crush the Hackers Before They Crush You *FDAnews Webinar* Oct. 18, 2013 — 1:30 p.m. – 3:00 p.m. EDT www.fdanews.com/CybersecurityPR2 - September 29, 2013 - FDAnews
FDAnews Announces Pay-to-Delay Settlements in the Wake of Activis Virtual Conference
Pay-to-Delay Settlements in the Wake of Activis; Current, Former FTC Officials Offer Answers **FDAnews Virtual Conference** Oct. 15, 2013 — 10:00 a.m. – 12:30 p.m. EDT - www.fdanews.com/PayToDelayPR2 - September 25, 2013 - FDAnews
FDAnews Announces: FDA Recordkeeping, Dangerous Documents and Writing for Compliance ™
FDA Recordkeeping, Dangerous Documents and Writing for Compliance ™; Presented by FDAnews; Nov. 13-14, 2013 – Bethesda, MD; http://www.fdanews.com/DangerousDocsPR2. - September 22, 2013 - FDAnews
Creative Biomart is Going to Sign Luciferase Supply Agreement with Kasain Laboratory
After a long-term contact and discussion, Creative Biomart finally agrees to sign a Luciferase supply agreement with Kasain Laboratory, especially Native Vibrio fischeri Luciferase (http://www.creativebiomart.net/description_390631_24.htm) until Kasain finishes its study projects. The official... - September 22, 2013 - Creative BioMart
FDAnews Announces Medical Device Mobile Apps Virtual Conference – Oct. 3, 2013
Medical Device Mobile Apps; The Biosense Case: FDA Sends First Warning; FDAnews Virtual Conference; Oct. 3, 2013 — 10:00 a.m. – 4:00 p.m. EDT; www.fdanews.com/MDMobileAppsVCPR2 - September 21, 2013 - FDAnews
SignaBlok Achieves Key in Vivo Proof of Concept for Treatment of Cancer and Sepsis
Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis - September 18, 2013 - SignaBlok, Inc.
International Polymer Solutions Debuts Corporate Video
Video provides overview of company products and services. - September 16, 2013 - International Polymer Solutions Inc.
Eighth Annual FDA Inspections Summit: Early Bird Registration Ends Sept. 20
Eighth Annual FDA Inspections Summit; New Powers, New Enforcement Posture, New Challenges; Presented by FDAnews; Oct. 23-25, 2013 – Bethesda, MD; www.fdanews.com/FDAInspectionsSummitPR2. - September 15, 2013 - FDAnews
AveXis Inc. Names Director, Scientific and Corporate Affairs
AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Mindy Du as the company’s new Director of Scientific and Corporate Affairs. This is an essential position within the company, as AveXis is focused on research/development of leading-edge technology for disease... - September 13, 2013 - AveXis Inc.